Clinical trial
A Phase III Multi-centre Double-blind Placebo Controlled Study Analysing the Efficacy and Safety of Daily Administration of a P2Y12 Inhibitor (Clopidogrel) for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT02404363 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Multi-centre Double-blind Placebo Controlled Study Analysing the Efficacy and Safety of Daily Administration of a P2Y12 Inhibitor (Clopidogrel) for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 11, 2016
- Completion date
- March 27, 2018
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, pancreas, locally advanced pancreatic cancer, metastatic pancreatic cancer